11-Deoxycortisol, Quantitative, Serum
11-deoxycortisol is formed by the adrenal land in the Zona Fasiculata and Reticularis from 17-hydroxy progesterone and is finally converted into cortisol by 11β-hydroxylase (CYP11B1). Therefore, measurement of serum or plasma 11-deoxycortisol can be used to detect 11β-hydroxylase deficiency. The deficiency of 11β-hydroxylase is a second leading cause of Congenital Adrenal Hyperplasia (CAH) and is characterized by decreased production of cortisol resulting in increased adrenocorticotropic hormone (ACTH) production from pituitary. Due to the block in the synthetic pathway the concentrations of the precursor steroid molecules,11-deoxycortisol, 17-hydroxyprogesterone, androstenedione, and 11-desoxycorticosterone are all elevated.
Metyrapone is a drug that inhibits the activity of 11β-hydroxylase and can be used to assess the function of the hypothalamic-pituitary-adrenal axis (HPA) after its administration by measuring levels of 11-deoxycortisol, ACTH and cortisol. In normal individuals the administration of metyrapone causes a reduction of plasma cortisol which stimulates the pituitary to secrete ACTH resulting in a 40 to 80-fold increase in plasma 11-deoxycortisol levels. In patients with primary or secondary adrenal insufficiency, the administration of metyrapone has little or no effect on 11-deoxycortisol levels. Similarly, in the patients with Cushing’s syndrome caused by ectopic ACTH or adrenal tumors, metyrapone administration does not result in changes in ACTH or 11-deoxycortisol concentrations.
- As an aid in the diagnosis of congenital adrenal hyperplasia
- Differential diagnosis of congenital adrenal hyperplasia due to 21α-hydroxylase deficiency
- Useful in screening of congenital adrenal hyperplasia in newborns along with 17α-hydroxyprogesterone
- Measurement of 11-deoxycortisol after metyrapone administration provide valuable information on pituitary-adrenal reserve
- Differential diagnosis of Cushing syndrome
Increased in:
- Adrenogenital syndrome due to 17-and 11-hydroxylase deficiency
- Congenital adrenal hyperplasia (CYP11B1, or 11β-hydroxylase deficiency)
- Administration of metyrapone
- Cushing Disease
- ACTH-producing tumors
Decreased in:
- Adrenal insufficiency
- 21-hydroxylase deficiency
- 17α-hydroxylase deficiency
- Preeclampsia
18 years or younger: < 320 ng/dL
Adults older than 18 years: 12-80 ng/dL
After single-dose overnight metyrapone test > 1700 ng/dL
Serum (SST), Urine in urine container.
Stability
- Ambient: 1 day
- Refrigerated: 7-14 days
- Frozen: 3 months
- Ann Intern Med. 1971;75:717-23 [PMID: 4330677]
- Am J Med. 1983;74:657-62 [PMID: 6837591]
- J Clin Endocrinol Metab. 2002;87:5470-5 [PMID: 12466339]
- J Clin Endocrinol Metab. 2006;91:2179-84 [PMID: 16551734]
- Steroids 2007;72:71-84 [PMID: 17157339]
- Mol Cell Endocrinol 2009;1-2:272-81. [PMID: 19007847]
- Clin Chim Acta 2010;3-4:222-8. [PMID: 19931522]
- Stewart PM, Krone NP. The Adrenal Cortex. Williams Textbook of Endocrinology. 12th ed. Saunders Company: Philadelphia, PA; 2011. Page 479-544
- Bertholf RL, Winter WE. The Adrenal Cortex. Textbook of Clinical Chemistry and Molecular Diagnostics. 5th ed. 2012. Page 1847-1904.